This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.
A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Global leader in APC-targeted immunotherapy technology
NYKODE THERAPEUTICS (NYKD-OL, MKT CAP ~$800M)
Proprietary immunotherapies targeting antigens to Antigen-Presenting Cell (APC) and generating strong CD8 killer T cell responses correlated with clinical responses in solid tumors
Modular, versatile platform
Easily incorporate new antigens and adapt to new diseases across oncology, infectious diseases and autoimmunity
Rapidly advancing wholly owned lead asset, VB10.16, immunotherapy for HPV16+ cancers
Reporting final data from C-02 with focus on durability in 1H 2023
Potentially registrational study in advanced cervical cancer to initiate 2023
Dose escalation study with KEYTRUDA®1 in head and neck cancer to initiate 1H2023
Strategic partnerships to advance clinical programs and commercialize assets worldwide2
Well-capitalized with a cash position of $206m at December 31, 2022
Note: KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Note: Genentech has an exclusive license to VB10.NEO. Collaboration and license to 5 programs with Regeneron. Collaboration and license with Adaptive Biotechnologies on SARS-CoV-2 T cell vaccine. Roche supplies atezolizumab; . Merck (MSD) supplies pembrolizumab
Announced positive immunogenicity results from a Phase 1/2a trial of VB10.NEO in multiple indications
Presented additional efficacy analysis from a Phase 2 trial of VB10.16 in advanced cervical cancer
Announced clinical collaboration and drug supply of KEYTRUDA® with MSD for the VB C-03 trial
Entered into strategic manufacturing partnership with Richter-Helm BioLogics
Announced expanded clinical development plan for VB10.16 in HPV16-positive cancers, including a potentially registrational trial in advanced cervical cancer (VB C-04).
Post Q4:
Announced collaboration with gynecologic study group GOG Foundation to conduct the VB C-04 trial in advanced cervical cancer.
Nykode Therapeutics AS published this content on 28 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 February 2023 15:25:36 UTC.
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeuticsâ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
NYKODE THERAPEUTICS 
